Abbott Labs (ABT) Stock News

Abbott (NYSE:ABT) has received CE Mark approval for an expanded indication of its Navitor™ TAVI system to treat patients with symptomatic, severe aortic stenosis who are at low or intermediate surgical risk. This expansion, supported by the VANTAGE trial data, makes Navitor available across all surgical risk categories in Europe.

The VANTAGE study demonstrated excellent outcomes, including a low 2.3% rate of all-cause mortality or fatal stroke/stroke with disability, no moderate or greater PVL at 30 days, and a 97% technical success rate. Additionally, the European Society of Cardiology announced updated guidelines upgrading recommendations for Abbott's MitraClip™ and TriClip™ therapies for treating heart valve diseases.

Abbott (NYSE:ABT) and the Big Ten Conference have launched Year 2 of their 'We Give Blood' drive competition, running from August 27 to December 5, 2025. The nationwide challenge involves all 18 Big Ten universities competing to inspire the most blood donations, with the winning school receiving $1 million from Abbott for student or community health initiatives.

The campaign addresses critical U.S. blood shortages, with some centers reporting less than one-day supply. Abbott is offering exclusive limited-edition Homefield designed T-shirts and hosting 12 Weekly One-Up Challenges during the football season. The University of Nebraska-Lincoln won the inaugural 2024 competition with nearly 4,000 donors, saving up to 12,000 lives. The 2025 winner will be announced at the Big Ten Championship Football Game on December 6 in Indianapolis.

Abbott (NYSE: ABT) reported strong second-quarter 2025 results with reported sales growth of 7.4% and organic sales growth of 7.5% excluding COVID-19 testing. The company achieved GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.26, reflecting double-digit growth year-over-year.

Key financial metrics include improved margins, with reported gross margin at 52.7% and adjusted gross margin at 57.0%, representing a 100 basis point increase. The company projects full-year 2025 organic sales growth of 7.5-8.0% excluding COVID-19 testing and adjusted diluted EPS of $5.10-$5.20.

Notable developments include FDA approval of the Tendyne™ TMVR system, completion of enrollment in the FlexPulse U.S. IDE trial, and plans for a new cardiovascular device manufacturing facility in Georgia by 2028. The company also declared its 406th consecutive quarterly dividend of $0.59 per share.

Abbott (NYSE:ABT) has scheduled its second-quarter 2025 financial results announcement for Thursday, July 17, 2025, before market opening. The company will host a live earnings conference call at 8 a.m. Central time (9 a.m. Eastern). Investors can access the webcast through Abbott's Investor Relations website at www.abbottinvestor.com. An archived version of the call will be made available later the same day.

A clinical trial of Abbott's (ABT) Healthy Food Rx program, presented at ADA's 85th Scientific Sessions, demonstrated significant benefits for diabetes patients. The study of 364 participants over six months showed improved diet quality with increased vegetable consumption (0.37 vs 0.03 servings/day) and fruit intake. Physical health status improved markedly in program participants (38% to 63%) compared to the control group (47% to 50%). Both groups saw significant A1C level improvements, decreasing by 0.7% in the intervention group and 1.2% in the control group. The program, launched in 2021, has reached over 1,700 participants in Stockton, California, where 60% of the population has diabetes or pre-diabetes. Participant satisfaction was notably high, with 98% satisfied and 97% utilizing most or all provided food.

Abbott (NYSE: ABT) has announced its 406th consecutive quarterly dividend of $0.59 per share, demonstrating a remarkable track record of consistent shareholder returns since 1924. The dividend will be paid on August 15, 2025, to shareholders of record as of July 15, 2025. The company has achieved an impressive milestone of increasing its dividend payout for 53 consecutive years, securing its position in the prestigious S&P 500 Dividend Aristocrats Index, which recognizes companies with at least 25 years of consecutive dividend increases.

Abbott (ABT) has received FDA approval for its Tendyne™ transcatheter mitral valve replacement (TMVR) system, a first-of-its-kind device that replaces malfunctioning mitral valves without open-heart surgery. The system is specifically designed for patients with severe mitral annular calcification (MAC) who are high-risk candidates for traditional surgery.

The innovative Tendyne system features a self-expanding valve that is delivered through a small chest incision and is fully repositionable during implantation. The device is available in multiple sizes to accommodate different patient anatomies and offers a new treatment option for patients who cannot undergo open-heart surgery or mitral repair with Abbott's MitraClip™ device.

Abbott's FreeStyle Libre® continuous glucose monitoring (CGM) technology has demonstrated groundbreaking results in reducing cardiovascular disease-related hospitalizations for diabetes patients. The REFLECT real-world studies show a 78% reduction in heart-related hospitalizations for Type 1 diabetes patients with prior severe low blood sugar episodes. For Type 1 diabetes patients with no prior cardiovascular disease history, hospitalizations decreased by 80%, while those with prior history saw a 49% reduction. The technology also showed similar benefits for Type 2 diabetes patients on insulin. This is particularly significant as diabetes affects approximately 589 million people globally, with diabetic patients being 2-4 times more likely to develop heart disease than non-diabetics. The findings suggest that Libre technology could lead to lower healthcare costs through reduced hospital admissions while helping patients better manage both their diabetes and cardiovascular health.

Cadrenal Therapeutics (NASDAQ: CVKD) reported its Q1 2025 financial results and corporate updates. Key highlights include: appointment of Dr. James Ferguson as Chief Medical Officer, a successful FDA Type D Meeting providing guidance for tecarfarin's Phase 3 trial, and a Collaboration Agreement with Abbott for the TECH-LVAD trial. The company completed technical transfer of tecarfarin manufacturing to a U.S. CDMO and conducted market research showing growth potential in the LVAD market. Financial results show R&D expenses of $1.7M (up from $0.6M in Q1 2024), G&A expenses of $2.3M (up from $1.1M), and a net loss of $3.8M. Cash position stands at $7.3M as of March 31, 2025, down from $10.0M at year-end 2024.